We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Books » GCP Enforcement Trends

Other Options

PDF Edition

$397.00

PDF Edition - 3-4 Copies (10% Off)

$357.00

PDF Edition - 5-6 Copies (15% Off)

$337.00

PDF Edition - 7-9 Copies (20% Off)

$317.00

PDF Edition - 10+ Copies (25% Off)

$297.00

GCP Enforcement Trends

$397.00
Books

Product Details

GCP Enforcement Trends

From January 2010 through June 2015, the FDA issued 89 warning letters to clinical investigators, sponsors and IRBs for good clinical practices (GCP) violations.

If you read all 89 one by one, you would find them to be compelling reading.

But, the real power of the warning letters comes from looking at them closely as a 5+ year continuum.

With the report in hand, you'll quickly become aware of the FDA's priorities and learn to recognize inspection red flags that almost always lead to GCP violations.

You'll see patterns to watch for in the FDA's GCP enforcement activities, and learn some surprising lessons that will help you stay in full compliance with the agency's requirements.

You'll go behind the scenes to learn about real-life inspection pitfalls and how to avoid them. The report recounts successful (and unsuccessful) attempts to prevent 483s from turning into warning letters and shares insights about others' past mistakes in real-life scenarios that include:

  • The site that tried to solve its problems managing continuing review, only to have the FDA to say the "improvements" actually made them worse.
  • A sponsor's carefully crafted informed consent documents that overlooked one of the most basic requirements.
  • The investigator who upended a trial by deviating from a basic element of the protocol without anyone noticing.
  • And more …

This management report shows you the real-life lessons you can learn from inspection results — findings that will help keep you in tune with GCP enforcement practices and avoid warning letters.

GCP Enforcement Trends might very well offer the best business knowledge you'll come across this year. Don't hesitate. Order your copy today.

 

PDF Edition

Available Format

PDF Edition — $397

Table of Contents

  • Introduction
  • IRB Enforcement Actions
  • Clinical Investigator Enforcement Actions
  • Sponsor Enforcement Actions
  • And More …

View the entire TOC

Who Will Benefit

  • Clinical trial managers
  • Clinical investigators
  • IRB members
  • Internal auditors
  • Regulatory affairs directors
  • Compliance officers
  • Legal counsel

Multi-user Access

Save money with a license agreement allowing significant numbers of users access to an electronic version of this book. For multi-user access to multiple titles, FDAnews offers the FDAnews Online Library — a personalized collection of FDAnews publications that is fully searchable. Contact Customer Service for a quote or more information.

Our Guarantee

Not satisfied with your publication? For the PDF version, you must notify FDAnews within 24 hours of receipt of purchase and we will refund 100 percent of your purchase price.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing